The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022.

: A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. But it is also through several failed clinical trials, that we were able to define new therapeutic approaches which improved TNBC patients' clinical outcomes Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients' therapies.